Close this search box.

Clinical Trial: SWOG S1803

SWOG S1803

Status: Open

Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)

Eligible for screening study DCP 001

Occupational Report & Pregnancy Report consent forms available upon request. Please contact Amber Boerner, or 406-969-6066, for the consents and for any questions.

S1803, PRO Sub-Study is closed to accrual, effective April 15, 2024.